Impact of Oxypurinol in Patients With Symptomatic Heart Failure. Results of the OPT-CHF Study

Joshua M. Hare, Brian Mangal, Joanne Brown, Charles Fisher, Ronald Freudenberger, Wilson S. Colucci, Douglas L. Mann, Peter Liu, Michael M. Givertz, Richard P. Schwarz

Research output: Contribution to journalArticle

Abstract

Objectives: This study evaluated whether a xanthine oxidase (XO) inhibitor, oxypurinol, produces clinical benefits in patients with New York Heart Association functional class III to IV heart failure due to systolic dysfunction receiving optimal medical therapy. Background: Increased XO activity may contribute to heart failure pathophysiology. Methods: Patients (n = 405) were randomized to oxypurinol (600 mg/day) or placebo. Efficacy at 24 weeks was assessed using a composite end point comprising heart failure morbidity, mortality, and quality of life. Results: The percentage of patients characterized as improved, unchanged, or worsened did not differ between those receiving oxypurinol or placebo. Oxypurinol reduced serum uric acid (SUA) by ∼2 mg/dl (p <0.001). In a subgroup analysis, patients with elevated SUA (>9.5 mg/dl, n = 108) responded favorably to oxypurinol (p = 0.02 for interaction term), whereas oxypurinol patients with SUA

Original languageEnglish (US)
Pages (from-to)2301-2309
Number of pages9
JournalJournal of the American College of Cardiology
Volume51
Issue number24
DOIs
StatePublished - Jun 17 2008
Externally publishedYes

Fingerprint

Oxypurinol
Heart Failure
Xanthine Oxidase
Uric Acid
Placebos
Serum
Quality of Life
Morbidity
Mortality

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Hare, J. M., Mangal, B., Brown, J., Fisher, C., Freudenberger, R., Colucci, W. S., ... Schwarz, R. P. (2008). Impact of Oxypurinol in Patients With Symptomatic Heart Failure. Results of the OPT-CHF Study. Journal of the American College of Cardiology, 51(24), 2301-2309. https://doi.org/10.1016/j.jacc.2008.01.068

Impact of Oxypurinol in Patients With Symptomatic Heart Failure. Results of the OPT-CHF Study. / Hare, Joshua M.; Mangal, Brian; Brown, Joanne; Fisher, Charles; Freudenberger, Ronald; Colucci, Wilson S.; Mann, Douglas L.; Liu, Peter; Givertz, Michael M.; Schwarz, Richard P.

In: Journal of the American College of Cardiology, Vol. 51, No. 24, 17.06.2008, p. 2301-2309.

Research output: Contribution to journalArticle

Hare, JM, Mangal, B, Brown, J, Fisher, C, Freudenberger, R, Colucci, WS, Mann, DL, Liu, P, Givertz, MM & Schwarz, RP 2008, 'Impact of Oxypurinol in Patients With Symptomatic Heart Failure. Results of the OPT-CHF Study', Journal of the American College of Cardiology, vol. 51, no. 24, pp. 2301-2309. https://doi.org/10.1016/j.jacc.2008.01.068
Hare, Joshua M. ; Mangal, Brian ; Brown, Joanne ; Fisher, Charles ; Freudenberger, Ronald ; Colucci, Wilson S. ; Mann, Douglas L. ; Liu, Peter ; Givertz, Michael M. ; Schwarz, Richard P. / Impact of Oxypurinol in Patients With Symptomatic Heart Failure. Results of the OPT-CHF Study. In: Journal of the American College of Cardiology. 2008 ; Vol. 51, No. 24. pp. 2301-2309.
@article{3c97ee9dc98a491d82e5f91e2ad7ab8a,
title = "Impact of Oxypurinol in Patients With Symptomatic Heart Failure. Results of the OPT-CHF Study",
abstract = "Objectives: This study evaluated whether a xanthine oxidase (XO) inhibitor, oxypurinol, produces clinical benefits in patients with New York Heart Association functional class III to IV heart failure due to systolic dysfunction receiving optimal medical therapy. Background: Increased XO activity may contribute to heart failure pathophysiology. Methods: Patients (n = 405) were randomized to oxypurinol (600 mg/day) or placebo. Efficacy at 24 weeks was assessed using a composite end point comprising heart failure morbidity, mortality, and quality of life. Results: The percentage of patients characterized as improved, unchanged, or worsened did not differ between those receiving oxypurinol or placebo. Oxypurinol reduced serum uric acid (SUA) by ∼2 mg/dl (p <0.001). In a subgroup analysis, patients with elevated SUA (>9.5 mg/dl, n = 108) responded favorably to oxypurinol (p = 0.02 for interaction term), whereas oxypurinol patients with SUA",
author = "Hare, {Joshua M.} and Brian Mangal and Joanne Brown and Charles Fisher and Ronald Freudenberger and Colucci, {Wilson S.} and Mann, {Douglas L.} and Peter Liu and Givertz, {Michael M.} and Schwarz, {Richard P.}",
year = "2008",
month = "6",
day = "17",
doi = "10.1016/j.jacc.2008.01.068",
language = "English (US)",
volume = "51",
pages = "2301--2309",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "24",

}

TY - JOUR

T1 - Impact of Oxypurinol in Patients With Symptomatic Heart Failure. Results of the OPT-CHF Study

AU - Hare, Joshua M.

AU - Mangal, Brian

AU - Brown, Joanne

AU - Fisher, Charles

AU - Freudenberger, Ronald

AU - Colucci, Wilson S.

AU - Mann, Douglas L.

AU - Liu, Peter

AU - Givertz, Michael M.

AU - Schwarz, Richard P.

PY - 2008/6/17

Y1 - 2008/6/17

N2 - Objectives: This study evaluated whether a xanthine oxidase (XO) inhibitor, oxypurinol, produces clinical benefits in patients with New York Heart Association functional class III to IV heart failure due to systolic dysfunction receiving optimal medical therapy. Background: Increased XO activity may contribute to heart failure pathophysiology. Methods: Patients (n = 405) were randomized to oxypurinol (600 mg/day) or placebo. Efficacy at 24 weeks was assessed using a composite end point comprising heart failure morbidity, mortality, and quality of life. Results: The percentage of patients characterized as improved, unchanged, or worsened did not differ between those receiving oxypurinol or placebo. Oxypurinol reduced serum uric acid (SUA) by ∼2 mg/dl (p <0.001). In a subgroup analysis, patients with elevated SUA (>9.5 mg/dl, n = 108) responded favorably to oxypurinol (p = 0.02 for interaction term), whereas oxypurinol patients with SUA

AB - Objectives: This study evaluated whether a xanthine oxidase (XO) inhibitor, oxypurinol, produces clinical benefits in patients with New York Heart Association functional class III to IV heart failure due to systolic dysfunction receiving optimal medical therapy. Background: Increased XO activity may contribute to heart failure pathophysiology. Methods: Patients (n = 405) were randomized to oxypurinol (600 mg/day) or placebo. Efficacy at 24 weeks was assessed using a composite end point comprising heart failure morbidity, mortality, and quality of life. Results: The percentage of patients characterized as improved, unchanged, or worsened did not differ between those receiving oxypurinol or placebo. Oxypurinol reduced serum uric acid (SUA) by ∼2 mg/dl (p <0.001). In a subgroup analysis, patients with elevated SUA (>9.5 mg/dl, n = 108) responded favorably to oxypurinol (p = 0.02 for interaction term), whereas oxypurinol patients with SUA

UR - http://www.scopus.com/inward/record.url?scp=44649122196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649122196&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2008.01.068

DO - 10.1016/j.jacc.2008.01.068

M3 - Article

C2 - 18549913

AN - SCOPUS:44649122196

VL - 51

SP - 2301

EP - 2309

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 24

ER -